Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE GOLDSTICK

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1508969445
CMS profile
67920
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$65,060.04

218 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 5 of 5; records 201–218 of 218 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE GOLDSTICK

NPI 1508969445 · CMS profile ID 67920

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–218 of 218 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508969445?year=2020&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–218 of 218 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508969445?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–218 of 218 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508969445?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–218 of 218 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508969445?year=2020&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

218 matching records · $65,060.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 218 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–218 of 218.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $2,160.0001/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751300457 CMS
EMD Serono, Inc. $88.3001/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751264773 CMS
Biogen, Inc. $19.7401/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269289 CMS
Biogen, Inc. $581.6901/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269269 CMS
Biogen, Inc. $7,200.0001/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269271 CMS
Biogen, Inc. $36.1401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269275 CMS
Biogen, Inc. $58.9301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269283 CMS
Biogen, Inc. $71.9501/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269285 CMS
Biogen, Inc. $89.2101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269287 CMS
Biogen, Inc. $101.8801/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269273 CMS
Biogen, Inc. $196.6401/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269277 CMS
Biogen, Inc. $16.5001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269279 CMS
Biogen, Inc. $125.4601/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269281 CMS
ACADIA Pharmaceuticals Inc $12.4401/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748557635 CMS
Genentech USA, Inc. $14.9501/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743046933 CMS
Acorda Therapeutics, Inc $22.1601/07/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716698605 CMS
Biogen, Inc. $0.9401/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269205 CMS
Biogen, Inc. $24.8701/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737269207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119,123.08 418
PY2020 $65,060.04 218
PY2021 $64,465.93 190
PY2022 $86,372.78 268
PY2023 $61,663.80 200
PY2024 $54,595.14 168
PY2025 $27,717.96 126

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $18,424.54 11
PY2025 Principal investigator $537,713.02 42
PY2024 Recipient $15,557.38 26
PY2024 Principal investigator $508,495.62 27
PY2023 Recipient $300.00 1
PY2023 Principal investigator $578,831.07 51
PY2022 Recipient $4,038.00 2
PY2022 Principal investigator $1,076,545.57 64
PY2021 Principal investigator $1,180,096.38 38
PY2020 Recipient $2,220.93 2
PY2020 Principal investigator $1,209,008.22 37
PY2019 Recipient $2,967.30 1
PY2019 Principal investigator $1,281,674.25 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $46,180.85 12/15/2025 Non-covered Recipient Entity
The University Of Cincinnati Foundation
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226120737
Principal investigator 1 TG Therapeutics, Inc. $4,002.90 12/10/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198925
Principal investigator 1 TG Therapeutics, Inc. $21,896.34 12/09/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198933
Recipient F. Hoffmann-La Roche AG $763.30 11/28/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537336
Principal investigator 1 TG Therapeutics, Inc. $45,000.00 11/24/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198935
Principal investigator 1 GENZYME CORPORATION $11,240.10 11/17/2025 Non-covered Recipient Entity
The University Of Cincinnati Foundation
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120726
Principal investigator 1 Genentech, Inc. $9,438.00 11/03/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677797
Principal investigator 1 TG Therapeutics, Inc. $26,263.06 11/01/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198931
Principal investigator 1 GENZYME CORPORATION $33,320.00 10/27/2025 Non-covered Recipient Entity
The University Of Cincinnati Foundation
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226120722
Principal investigator 1 Genentech, Inc. $14,517.00 10/17/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677791
Principal investigator 1 Genentech, Inc. $6,570.00 10/08/2025 Non-covered Recipient Entity
University of Cincinnati
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211677719
Recipient F. Hoffmann-La Roche AG $424.06 10/03/2025 Covered Recipient Physician Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial No dispute reported 06/30/2026 1211537313
Recipient F. Hoffmann-La Roche AG $1,090.56 10/02/2025 Covered Recipient Physician Efficacy Tolerability of Ocrelizumab in African Americans Hispanic Americans vs Caucasians No dispute reported 06/30/2026 1211537331
Principal investigator 1 Genentech, Inc. $6,950.00 10/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
OCARINA I No dispute reported 06/30/2026 1211677759
Principal investigator 1 Genentech, Inc. $5,809.47 10/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677793
Principal investigator 1 TG Therapeutics, Inc. $35,927.72 09/30/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198897
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 09/25/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198917
Recipient F. Hoffmann-La Roche AG $2,174.11 09/24/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537340
Principal investigator 1 Genentech, Inc. $7,258.50 09/19/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677789
Principal investigator 1 TG Therapeutics, Inc. $32,424.59 08/31/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198895
Principal investigator 1 TG Therapeutics, Inc. $1,868.02 08/25/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198915
Principal investigator 1 Genentech, Inc. $6,597.00 08/20/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
OCARINA I No dispute reported 06/30/2026 1211677761
Principal investigator 1 TG Therapeutics, Inc. $1,868.02 08/20/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198913
Principal investigator 1 TG Therapeutics, Inc. $1,868.02 08/18/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198911
Principal investigator 1 EMD Serono, Inc. $26,062.00 08/14/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118563
Principal investigator 1 TG Therapeutics, Inc. $800.58 08/14/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198909
Principal investigator 1 TG Therapeutics, Inc. $1,067.44 08/05/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198907
Principal investigator 1 TG Therapeutics, Inc. $13,755.84 07/31/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198893
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/21/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198905
Principal investigator 1 GENZYME CORPORATION $38,450.00 07/14/2025 Non-covered Recipient Entity
The University Of Cincinnati Foundation
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226120673
Principal investigator 1 TG Therapeutics, Inc. $23,368.02 06/01/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198867
Principal investigator 1 Genentech, Inc. $10,995.00 05/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
OCARINA I No dispute reported 06/30/2026 1211677749
Recipient F. Hoffmann-La Roche AG $6,011.55 05/13/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537306
Principal investigator 1 GENZYME CORPORATION $6,530.00 05/05/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081971
Principal investigator 1 Genentech, Inc. $181.20 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677785
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 04/28/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198889
Recipient F. Hoffmann-La Roche AG $6,022.93 04/17/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537303
Principal investigator 1 Genentech, Inc. $7,126.00 04/16/2025 Non-covered Recipient Entity
University of Cincinnati
First in human study RO7121932 No dispute reported 06/30/2026 1211677735
Recipient F. Hoffmann-La Roche AG $244.13 04/08/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537328
Recipient F. Hoffmann-La Roche AG $436.50 04/05/2025 Covered Recipient Physician Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211537309
Recipient F. Hoffmann-La Roche AG $436.36 03/31/2025 Covered Recipient Physician OCARINA I No dispute reported 06/30/2026 1211537318
Recipient F. Hoffmann-La Roche AG $423.66 03/31/2025 Covered Recipient Physician OCARINA I No dispute reported 06/30/2026 1211537321
Recipient F. Hoffmann-La Roche AG $397.38 03/31/2025 Covered Recipient Physician OCARINA I No dispute reported 06/30/2026 1211537325
Principal investigator 1 TG Therapeutics, Inc. $17,571.67 03/31/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198865
Principal investigator 1 Genentech, Inc. $12,664.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
OCARINA I No dispute reported 06/30/2026 1211677757
Principal investigator 1 GENZYME CORPORATION $5,498.00 03/17/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226081966
Principal investigator 1 Genentech, Inc. $9,288.00 03/05/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211677783
Principal investigator 1 TG Therapeutics, Inc. $13,758.48 02/28/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198863
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 02/26/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198885
Principal investigator 1 Genentech, Inc. $8,096.00 02/04/2025 Non-covered Recipient Entity
University of Cincinnati
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211677717
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 01/30/2025 Non-covered Recipient Entity
University of Cincinnati
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198883
Principal investigator 1 Genentech, Inc. $4,897.00 01/14/2025 Non-covered Recipient Entity
University of Cincinnati
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211677715
Principal investigator 1 Eli Lilly and Company $457.72 01/09/2025 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893556